Results 281 to 290 of about 250,824 (344)

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

open access: yesBMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou   +6 more
wiley   +1 more source

Dynamics of natural killer cell function upon recurrent stimulation

open access: yesBiotechnology Progress, EarlyView.
Weekly stimulation of peripheral blood‐derived NK cells with engineered K562 feeder cells resulted in two distinct growth phases, shifting around Day 21–26. Cells in growth phase 2 exhibited slower growth, reduced metabolic activity, and lower cytotoxicity than cells from growth phase 1, which has implications for NK cell biomanufacturing.
Jennifer One   +4 more
wiley   +1 more source

Nanogel‐Mediated Immunotherapy to Tackle Cancer and Inflammatory Diseases

open access: yesChemistryEurope, EarlyView.
Nanogels formed through self‐assembly, microemulsion, or precipitation polymerization method enable precise delivery of immunotherapeutic factors and immune cell targeting, thus effectively modulating immune responses. This review highlights recent advances in stimuli‐responsive nanogel design, underlying mechanisms, and their potentials to tackle ...
Ziwen Zhang   +7 more
wiley   +1 more source

STAT3 Signaling Mediates Agomelatine Restoration of Prefrontal Cortex Synaptic Plasticity in Chronic Social Defeat Stress Mice. [PDF]

open access: yesMol Neurobiol
Lee CW   +9 more
europepmc   +1 more source

Pathogenesis and potential therapeutic targets of trichorhinophalangeal syndrome; lessons obtained from animal studies

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Trichorhinophalangeal syndrome (TRPS) is a rare genetic disease inherited in an autosomal dominant manner. It occurs in 1 in 100,000 people globally and is caused by several types of mutations of the TRPS1 gene. Since the first human patient was reported in 1966, typical and atypical pathologies, disease courses, and treatment case ...
Naoya Saeki   +6 more
wiley   +1 more source

Targeting MGAT4A‐Mediated N‐Glycosylation as a Therapeutic Strategy to Inhibit Glioblastoma Stem Cell Invasion

open access: yesExploration, EarlyView.
ABSTRACT Glioblastoma (GBM) is the most aggressive type of primary brain tumor, and its invasive properties contribute significantly to incomplete surgical resection and tumor recurrence. Despite extensive clinical efforts to mitigate GBM invasion, targeted therapies against GBM stem cells (GSCs), which drive invasion, remain incompletely understood ...
Rui Niu   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy